Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImPrEP LEN Brasil Study
NCT07497594Recruiting
- Sponsor
- Fundação Oswaldo Cruz
- Start
- Feb 2026
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of lenacapavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Fundação Oswaldo Cruz. Primary endpoints: Proportion of participants who remain persistent on Lenacapavir pre-exposure prophylaxis at 24 months and Time to discontinuation of Lenacapavir pre-exposure prophylaxis up to 24 months. Started Feb 2026; status: recruiting.
02
Drugs
lenacapavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07497594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07497594.